F2G (United Kingdom)

Homepage: f2g.com

Alternate names: F2G, F2G - The Rare Fungal Disease Company, F2G Limited, F2G Ltd

ROR: 007f2f085

OpenAlex ID: I4405270194

Alternatives to antibiotics—a pipeline portfolio review

2016 · Lloyd Czaplewski, Richard Bax, et al. · The Lancet Infectious Diseases · 881

Antibiotic development — economic, regulatory and societal challenges

2019 · Christine Årdal, Manica Balasegaram, et al. · Nature Reviews Microbiology · 485

PDF

Developmental roadmap for antimicrobial susceptibility testing systems

2018 · the JPIAMR AMR-RDT Working Group on Antimicrobial Resistance and Rapid Diagnostic Testing, Alex van Belkum, et al. · Nature Reviews Microbiology · 350

PDF

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

2016 · Jason D. Oliver, Graham E. M. Sibley, et al. · Proceedings of the National Academy of Sciences · 295

PDF

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

2022 · Mark S. Butler, Valeria Gigante, et al. · Antimicrobial Agents and Chemotherapy · 288

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach

2016 · John H Rex, Kevin Outterson · The Lancet Infectious Diseases · 118

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus

2018 · Saskia du Pré, Nicola Beckmann, et al. · Antimicrobial Agents and Chemotherapy · 114

PDF

A Rheic cause for the Acadian deformation in Europe

2007 · N.H. WOODCOCK, N.J. SOPER, et al. · Journal of the Geological Society · 112

White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs

2017 · Helen W Boucher, Paul G Ambrose, et al. · The Journal of Infectious Diseases · 104

PDF

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates

2017 · J. B. Buil, A. J. M. M. Rijs, et al. · Journal of Antimicrobial Chemotherapy · 101

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

2025 · Johan A Maertens, George R Thompson, et al. · The Lancet Infectious Diseases · 90

Aspergillus fumigatus strains that evolve resistance to the agrochemical fungicide ipflufenoquin in vitro are also resistant to olorofim

2023 · Norman van Rhijn, Isabelle S. R. Storer, et al. · Nature Microbiology · 87

PDF

Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans

2017 · Nathan P. Wiederhold, Derek Law, et al. · Journal of Antimicrobial Chemotherapy · 86

Designing development programs for non-traditional antibacterial agents

2019 · John H. Rex, Holly Fernandez Lynch, et al. · Nature Communications · 83

PDF

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis

2018 · Nathan P. Wiederhold, Laura K. Najvar, et al. · Antimicrobial Agents and Chemotherapy · 81

PDF

Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

2017 · William W. Hope, Laura McEntee, et al. · mBio · 79

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020

2021 · Kevin Outterson, Ebiowei S F Orubu, et al. · Clinical Infectious Diseases · 77

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

2018 · George H Talbot, Anita Das, et al. · The Journal of Infectious Diseases · 77

The rapid assignment of ruminal fungi to presumptive genera using ITS1 and ITS2 RNA secondary structures to produce group-specific fingerprints

2005 · Danny S. Tuckwell, Matthew J. Nicholson, et al. · Microbiology · 77

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance

2019 · William Hope, Neil R. H. Stone, et al. · mBio · 71

PDF

In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

2017 · Chayanika Biswas, Derek Law, et al. · Medical Mycology · 67

Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

2017 · John H Rex, George H Talbot, et al. · Clinical Infectious Diseases · 67

PDF

Efficacy of Olorofim (F901318) against Aspergillus fumigatus , A. nidulans , and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease

2019 · S. Seyedmousavi, Y. C. Chang, et al. · Antimicrobial Agents and Chemotherapy · 58

In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents

2021 · Ourania Georgacopoulos, Natalie Nunnally, et al. · Journal of Fungi · 51

PDF

Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials

2019 · Emmanuel Weiss, Jean-Ralph Zahar, et al. · Clinical Infectious Diseases · 51

PDF

Works count: 104

Citation count: 11,760